Evolus Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
EOLS$6.81-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share data)
| Common Stock · Additional Paid In Capital · AccumulatedOther Comprehensive Loss · Accumulated Deficit · Total | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2021 | 55,576,988 | $1 | $504,757 | $— | $(422,882) | $81,876 |
| Issuance of common stock in connection with the incentive equity plan | 683,582 | — | 539 | — | — | 539 |
| Stock-based compensation expense | — | — | 10,833 | — | — | 10,833 |
| Net loss | — | — | — | — | (74,412) | (74,412) |
| Other comprehensive loss | — | — | — | (337) | — | (337) |
| Balance at December 31, 2022 | 56,260,570 | $1 | $516,129 | $(337) | $(497,294) | $18,499 |
| Issuance of common stock in connection with the incentive equity plan | 950,051 | — | 224 | — | — | 224 |
| Issuance of common stock in connection with Symatese Europe Agreement | 610,000 | — | 5,905 | — | — | 5,905 |
| Stock-based compensation | — | — | 16,458 | — | — | 16,458 |
| Net loss | — | — | — | — | (61,685) | (61,685) |
| Other comprehensive loss | — | — | — | (90) | — | (90) |
| Balance at December 31, 2023 | 57,820,621 | $1 | $538,716 | $(427) | $(558,979) | $(20,689) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.